Logo
Banner

Development of Specific Therapies Against A. Baumannii

Due to its ability to develop resistance to multiple antibiotics, A. baumannii is classified as a priority pathogen by the World Health Organization (WHO) and is considered a serious threat to public health. In light of the emergence of antibiotic-resistant superbugs like A. baumannii, it has become crucial to develop targeted therapies. Ace Infectious is committed to creating innovative and effective solutions to tackle this urgent global health crisis.

Specific Therapies against A. Baumannii

Developing targeted therapies against A. baumannii is challenging due to its diverse mechanisms of antibiotic resistance. One strategy is to identify essential targets unique to the bacterium and design drugs that selectively attack them without harming human cells. Another approach is to use combination therapies that target multiple pathways within the bacterium, making it difficult for the bacteria to develop resistance.

Specific Therapy Development Services Against A. Baumannii

  • Researchers often use cell and animal models to study A. baumannii infections and test potential treatments. We specialize in the development of A. baumannii infection models, and provide solutions to construct an A. baumannii infection model.
  • One of the key factors contributing to the success of A. baumannii as a superbug is its cell wall, which provides protection against host defenses and antibiotics. We offer a range of services aimed at developing therapies targeting the cell wall synthesis of A. baumannii.
  • A. baumannii's ability to acquire iron from its host is a key factor in its superbug status. To combat this, we provide therapy development services that specifically target iron acquisition in A. baumannii.
  • One of the critical factors that contribute to the virulence of A. baumannii is its Type IV Secretion Systems (T4SSs). These intricate molecular machines enable the bacterium to transmit DNA and proteins to other cells, including genes that confer resistance to antibiotics. By targeting T4SSs, we can potentially prevent the spread of antibiotic resistance and improve treatment options for A. baumannii infections.
  • The two-component regulatory system (TCS) of A. baumannii plays a crucial role in its virulence and antibiotic resistance, making it a promising target for therapy development. We offer development services targeting TCS of A. baumannii to combat this superbug.

Several Technologies for Development

We offer several technology methods that can be used for developing specific therapies against A. baumannii:

  • High-throughput screening
  • Microfluidics
  • CRISPR-Cas9
  • Phage therapy
  • Artificial intelligence

The emergence of superbugs like A. baumannii has created an urgent need for the development of specific therapies that can combat antibiotic-resistant bacteria. Ace Infectious is at the forefront of developing effective therapies against A. baumannii. Our team of experts is dedicated to advancing the development of these therapies to address the global health challenge posed by superbugs.

To learn more about innovative and effective solutions, please contact us.

References

  1. Lee C R, et al. Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol, 2017;7:55.
  2. McConnell M J, et al. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev, 2013;37(2):130-155.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Get in touch with our team immediately.